Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

Veru Inc. (NASDAQ: VERU) said it will present at the 2026 Obesity & Weight Loss Drug Development Summit in Boston (July 14–16, 2026). The company’s CEO Mitchell Steiner will discuss combining GLP-1s with SARMs to address sarcopenic obesity. Veru also outlined its Phase 2b PLATEAU enobosarm+semaglutide study (about 200 older patients), with interim analysis expected at 32 weeks in 1Q 2027 and topline data in 4Q 2027.

Original reporting
Published Jul 7, 2026, 1:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 7, 2026, 1:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day — source image
Decision brief

The 30-second read

$VERUNeutralLow
01

Why it matters

This release mainly publicizes where and when Veru’s leadership/science team will discuss the obesity program, reiterating the PLATEAU Phase 2b endpoint structure and expected interim/topline timing.

02

Market read

For VERU, the market takeaway is schedule/timeline visibility for the PLATEAU Phase 2b program rather than new clinical evidence.

03

What to watch

Any real price catalyst would likely come from the upcoming interim analysis (32 weeks) or topline data (4Q27), not from the conference schedule itself.

Relevance 4/10Novelty 4/10Timing: Ahead of the July 14-16, 2026 obesity summit presentations (July 14 workshop; July 15 main talk).

Background

Veru is a late clinical-stage biopharma developing enobosarm (SARM) for obesity in combination with GLP-1 RA therapy, plus sabizabulin for inflammatory/atherosclerotic cardiovascular disease.

Company-level read

Ticker impact

$VERUNeutralMedium confidence
Context

Veru announced it will present PLATEAU Phase 2b obesity data plans (interim at 32 weeks in 1Q27; topline in 4Q27) at a July 14-16 summit.

Expected impact

Likely limited/short-lived reaction unless accompanied by new data or guidance beyond the already-stated timeline.

Evidence & confidence

The article is a scheduled presentation/PR update with no new efficacy/safety results; the only actionable items are timing reiterations and the Novo Nordisk clinical supply agreement reference.

Market effects

Reinforces ongoing competitive focus on next-gen obesity regimens combining GLP-1 RA with muscle-sparing approaches (SARM concept).

Primarily US biotech sentiment; no specific regional macro linkage.

Limited global impact absent new clinical readouts or regulatory developments.

Counterpoint

Traders may discount the PR because it contains no new trial results—only planned presentations and forward-looking timelines.

Key entities

  • Veru Inc.

    NASDAQ-listed biopharmaceutical company presenting obesity program updates at the July 14-16, 2026 summit.

  • Enobosarm

    Oral SARM being studied to improve body composition and preserve lean mass during GLP-1 RA weight loss.

  • Novo Nordisk

    Referenced as having a clinical supply agreement for the PLATEAU Phase 2b study (details via June 2, 2026 8-K).

Related articles

$VERUMed

Veru presents data on enobosarm for obesity treatment

Veru Inc. (VERU) presented Phase 2b QUALITY study data at ObesityWeek 2026, showing enobosarm 3mg plus semaglutide helped patients aged 65+ with obesity gain lean mass and maintain physical function. The Phase 2b PLATEAU trial, with 239 patients, is ongoing, with interim data expected in Q1 2027. Veru has a clinical supply agreement with Novo Nordisk and a U.S. patent for the combination therapy.

$VERUMedAI 8/10

Veru executive to present obesity drug data at industry conference

Veru Inc. (VERU) will present obesity drug data at ObesityWeek 2026. Dr. Gary Barnette will discuss physical function in older patients using a GLP-1 receptor agonist from the QUALITY study. The company's Phase 2b PLATEAU trial has enrolled 239 patients, exceeding targets. Interim results are expected in Q1 2027, with final data in Q4 2027, according to the company.

$VERUMed

Why is Veru stock gaining today?

Veru Inc. (VERU) shares rose 1.8% after Oppenheimer reiterated its Outperform rating and $24 price target, citing confidence in enobosarm's Phase 2b trial results. The trial, fully enrolled with 239 patients, aims to show lean body mass preservation and fat loss benefits. Veru holds a U.S. patent for the enobosarm-semaglutide combination until 2044. The stock traded at $2.23, below its 52-week high of $7.33 but above its low of $2.05.

$VERUHighAI 8/10

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™)…

VERU INC. (VERU) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib